Health Trials

The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial

ConditionUrinary Bladder, Overactive
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexFemale
Age18+
SponsorFar Eastern Memorial Hospital

About this trial

The optimal medication for women with nocturia remains uncertain. This clinical trial aimed to determine the most effective medication for women with overactive bladder and nocturia. Its primary objectives were to answer the following questions:

Which medication is most effective for women with nocturia? Which medication has the least effect on heart rate variability in women with nocturia?

Eligibility criteria

Qualifiers

>18 years old.

female patients with overactive bladder syndrome

Disqualifiers

Clinically significant dysuria (inability to urinate, difficulty urinating).

Severe stress urinary incontinence (urinary incontinence caused by coughing).

Mixed urinary incontinence mainly caused by stress urinary incontinence (urinary incontinence caused by coughing as the main symptom).

Contraindications to antimuscarinic drugs or adrenergic receptor agonists.

Trial design

Treatments tested in this trial

  • Mirabegron 25mg
  • Solifenacin 5 mg
  • Tolterodine 4 mg
  • Oxybutynin ER 5 mg

Treatment groups

220 Participants
are divided into 4 treatment groups

Sponsors and collaborators

Far Eastern Memorial Hospital

Lead sponsor

Source ClinicalTrials.gov